Volume 86, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Universities Allied for Essential Medicines organized its first Neglected Diseases and Innovation Symposium to address expanding roles of public sector research institutions in innovation in research and development of biomedical technologies for treatment of diseases, particularly neglected tropical diseases. Universities and other public research institutions are increasingly integrated into the pharmaceutical innovation system. Academic entities now routinely undertake robust high-throughput screening and medicinal chemistry research programs to identify lead compounds for small molecule drugs and novel drug targets. Furthermore, product development partnerships are emerging between academic institutions, non-profit entities, and biotechnology and pharmaceutical companies to create diagnostics, therapies, and vaccines for diseases of the poor. With not for profit mission statements, open access publishing standards, open source platforms for data sharing and collaboration, and a shift in focus to more translational research, universities and other public research institutions are well-placed to accelerate development of medical technologies, particularly for neglected tropical diseases.

[open-access] Freely available online through the Open Access option.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Adli M, Kleinert S, Smith SK, Ganten D, , 2010. Academic medicine must take its global role: the M8 Alliance of Academic Health Centers and Medical Universities. Lancet 376: 11971198.[Crossref] [Google Scholar]
  2. Hotez PJ, Thompson TG, , 2009. Waging peace through neglected tropical disease control: a US foreign policy for the bottom billion. PLoS Negl Trop Dis 3: e346.[Crossref] [Google Scholar]
  3. The George Institute for International Health, 2009. Global Funding of Innovation for Neglected Diseases (G-FINDER). Available at: https://studies.thegeorgeinstitute.org/gfinder_report/index.jsp. Accessed May 25, 2011. [Google Scholar]
  4. Universities Allied for Essential Medicines, 2009. Global Access Licensing Framework. Available at: http://essentialmedicine.org/archive/global-access-licensing-framework-galf-v20. Accessed May 25, 2011. [Google Scholar]
  5. Association of University Technology Managers, 2009. University Principles on Global Access to Medicines. Available at: http://www.autm.net/Content/NavigationMenu/TechTransfer/GlobalHealth/statementofprincliples.pdf. Accessed May 25, 2011. [Google Scholar]
  6. 1999. Principles and guidelines for recipients of NIH research grants and contracts on obtaining and disseminating biomedical research resources. Fed Regist 64. [Google Scholar]
  7. National Institutes of Health, 2003. Final NIH Statement on Sharing Research Data. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html. Accessed May 25, 2011 [Google Scholar]
  8. National Institutes of Health, 2004. NIH Policy on Sharing of Model Organisms for Biomedical Research. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-042.html. Accessed May 25, 2011. [Google Scholar]
  9. National Institutes of Health, 2008. Revised Policy on Enhancing Public Access to Archived Publications Resulting from NIH-Funded Research. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-033.html. Accessed May 25, 2011. [Google Scholar]
  10. Human MicroBiome Project. Available at: https://commonfund.nih.gov/hmp/. Accessed October 6, 2011. [Google Scholar]
  11. Eukaryotic Pathogen Database. Available at: http://eupathdb.org/eupathdb/. Accessed October 6, 2011. [Google Scholar]
  12. Influenza Research Database. Available at: http://www.fludb.org/brc/home.do?decorator=influenza. Accessed October 6, 2011. [Google Scholar]
  13. National Cooperative Drug Discovery Group. Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-95-014.html. Accessed October 6, 2011. [Google Scholar]
  14. Spiegel JM, Dharamsi S, Wasan KM, Yassi A, Singer B, Hotez PJ, Hanson C, Bundy DA, , 2010. Which new approaches to tackling neglected tropical diseases show promise? PLoS Med 7: e1000255.[Crossref] [Google Scholar]
  15. Gershkovich P, Sivak O, Wasan EK, Magil AB, Owen D, Clement JG, Wasan KM, , 2010. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). J Antimicrob Chemother 65: 26102613.[Crossref] [Google Scholar]
  16. Wasan KM, Thornton SJ, Bell I, Goulding RE, Gretes M, Gray AP, Hancock RE, Campbell B, , 2009. The global access initiative at the University of British Columbia (UBC): availability of UBC discoveries and technologies to the developing world. J Pharm Sci 8: 791794.[Crossref] [Google Scholar]
  17. Franco-Paredes C, Rouphael N, del Rio C, Santos-Preciado JI, , 2006. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. Int J Infect Dis 10: 93102.[Crossref] [Google Scholar]
  18. World Health Organization, 2010. Global Tuberculosis Control. WHO Report 2010. Geneva, Switzerland: World Health Organization. [Google Scholar]
  19. Greenwood BM, Bojang K, Whitty CJ, Targett GA, , 2005. Malaria. Lancet 365: 14871498.[Crossref] [Google Scholar]
  20. Love JH, Hubbard T, , 2009. Prizes for innovation of new medicines and vaccines. Ann Health Law 18: 155186. [Google Scholar]
  21. World Health Assembly, 2008. The annex is the global strategy on public health, innovation and intellectual property. Proceedings of the 61st World Health Assembly. May 19–24, 2008. Geneva, Switzerland. [Google Scholar]
  22. Oxfam International, 2008. Ending the R&D Crisis in Public Health, Oxfam Briefing Paper. Avaialable at: http://www.oxfam.org/sites/www.oxfam.org/files/bp122-randd-crisis-public-health.pdf. Accessed May 25, 2011. [Google Scholar]
  23. Global HTC, Incentives & Innovative Financing Working Group, 2009. Current and Proposed Incentive Mechanisms. Available at: http://www.ghtcoalition.org/files/GHTC_Incentive_Mechanisms_List.pdf. Accessed May 25, 2011. [Google Scholar]
  24. US Food and Drug Administration, 2011. Designating an Orphan Product: Drugs and Biologics. Available at: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm. Accessed September 5, 2011. [Google Scholar]
  25. Redington L, , 2009. The Orphan Drug Act of 1983: a case study of issue framing and the failure to effect policy change from 1990 to 1994. PhD dissertation, University of North Carolina, Chapel Hill, NC. [Google Scholar]
  26. Love J, , 1992. Comments on the Orphan Drug Act and government sponsored monopolies for marketing pharmaceutical drugs. United States Senate, Committee on the Judiciary, Subcommittee on Antitrust, Monopolies and Business Rights, Anticompetitive Abuse of the Orphan Drug Act: Invitation to High Prices hearing. Serial Number J-102-48:265. [Google Scholar]
  27. Matheny J, Smith B, Courtney B, Mair M, , 2009. Drug and vaccine development for infectious diseases: the value of priority review vouchers. Clin Pharmacol Ther 85: 571572.[Crossref] [Google Scholar]
  28. Lexchin J, , 2010. One step forward, one step sideways? Expanding research capacity for neglected diseases. BMC Int Health Hum Rights 10: 20.[Crossref] [Google Scholar]
  29. Love J, , 2010. Written Submission to the US Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing on Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures on the Topic of Transparency, Cost Benefit Analysis and De-Linkage of Cost of R&D from Price of the Products. [Google Scholar]
  30. World Health Organization, 2006. Advanced market commitments for vaccines. Available at: http://www.who.int/immunization/newsroom/amcs/en/index.html. Accessed May 25, 2011. [Google Scholar]
  31. Brookings Global Health Initiative Snapshot Series, 2008. Advance Market Commitments for Vaccines. Available at: http://www.brookings.edu/~/media/Files/Projects/globalhealth/healthsnapshots/vaccines.pdf. Accessed September 27, 2011. [Google Scholar]
  32. Global Alliance for Vaccines and Immunisation. Available at: http://www.gavialliance.org/funding/pneumococcal-amc/. Accessed September 27, 2011. [Google Scholar]
  33. Glover GJ, , 2007. The influence of market exclusivity on drug availability and medical innovations. AAPS J 9: e312e316.[Crossref] [Google Scholar]
  34. Usher AD, , 2011. GAVI takes steps to address funding woes. Lancet 377: 453.[Crossref] [Google Scholar]
  35. Light DW, , 2009. Advanced Market Commitments: Current Realities and Alternate Approaches. Amsterdam, The Netherlands: Health Action International Europe/Medico International. [Google Scholar]
  36. Knowledge Ecology International, 2011. Available at: http://keionline.org/microsoft-timeline.
  37. Love J, , 2008. The role of prizes in developing low-cost, point-of-care rapid diagnostic tests and better drugs for tuberculosis. MSF Expert Meeting on IGWG and R&D for Tuberculosis. [Google Scholar]
  38. World Health Organization, 2009. Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis: Proposal by Bangladesh, Barbados, Bolivia and Suriname. Geneva, Switzerland: World Health Organization. [Google Scholar]
  39. Oxfam International, 2008. Ending the R&D crisis in public health. Oxfam Briefing Paper. [Google Scholar]
  40. Grace CK, Kyle M, , 2009. Innovating for the Health of All; Comparative advantages of push and pull incentives for technology development: lessons for neglected disease technology development. Global Forum for Health Research 6: 147151. [Google Scholar]
  41. Maxmen A, , 2010. Driving innovation: ready, set, go! Cell 140: 171173.[Crossref] [Google Scholar]
  42. Ekins S, Williams AJ, , 2010. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. Lab Chip 10: 1322.[Crossref] [Google Scholar]
  43. Hecht R, Wilson P, Palriwala A, , 2009. Improving health R&D financing for developing countries: a menu of innovative policy options. Health Aff (Millwood) 28: 974985.[Crossref] [Google Scholar]
  44. Ettling J, , 2000. The Germ of Laziness: Rockefeller Philanthropy and Public Health in the New South. Lincoln, NE: iUniverse, [Google Scholar]
  45. Zarocostas J, , 2010. First antiretroviral patent in global drug pool puts pressure on companies to follow suit. BMJ 341: c5514.[Crossref] [Google Scholar]
  46. Community of Science, 2010. COS Funding Opportunities. Available at: http://fundingopps.cos.com/about/fundingopps.shtml. Accessed September 27, 2011. [Google Scholar]
  47. NEWAID. The NEWAID Foundation. Available at: http://newaid.org/. Accessed October 6, 2011. [Google Scholar]
  48. InnoCentive. InnoCentive. Available at: http://www.innocentive.com/. Accessed October 6, 2011. [Google Scholar]
  49. Tres Cantos Medicines. Available at: http://www.gsk.com/collaborations/tres-cantos.htm. Accessed October 6, 2011.
  50. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH, , 2011. BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis 5: e985.[Crossref] [Google Scholar]
  51. Emory University. Molecules to Mankind PhD Program. Available at: http://m2m.emory.edu. Accessed October 6, 2011. [Google Scholar]
  52. Creative Commons Licenses. Available at: http://creativecommons.org/licenses/. Accessed October 6, 2011.
  53. Open Source Drug Discovery. Available at: http://www.osdd.net/. Accessed October 6, 2011.
  54. Masum H, Harris R, , 2011. Open Source for Neglected Diseases: Magic Bullet or Mirage? Center for Global Health R&D Policy Assessment, Results for Development Institute. [Google Scholar]
  55. Friend SH, , 2010. The need for precompetitive integrative bionetwork disease model building. Clin Pharmacol Ther 87: 536539.[Crossref] [Google Scholar]
  56. GNU General Public License, 2010.
  57. Hope J, , 2008. The Open Source Revolution and Biotechnology. Cambridge, MA: Harvard University Press.[Crossref] [Google Scholar]
  58. Cambia. Available at: http://www.cambia.org/daisy/cambia/home.html. Accessed October 6, 2011.
  59. Nolan-Stevaux KM, , 2007. Open source biology: a means to address the access & research gaps? Santa Clara Comput High Technol Law J J23: 271316. [Google Scholar]
  60. Maurer SM, Rai A, Sali A, 2004 Finding cures for tropical diseases: is open source an answer? PLoS Med 1: e56.[Crossref] [Google Scholar]
  61. Tropical Disease Initiative. Available at: http://tropicaldisease.org/. Accessed October 6, 2011.
  62. Marden E, , 2010. Open source drug development: a path to more accessible drugs and diagnostics? Minn J Law Sci Technol http://mjlst.umn.edu/ 11: 217266. [Google Scholar]
  63. Woelfle M, Seerden JP, de Gooijer J, Pouwer K, Olliaro P, Todd MH, , 2011. Resolution of praziquantel. PLoS Negl Trop Dis 5: e1260.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 27 Sep 2011
  • Accepted : 01 Oct 2011
  • Published online : 01 Jan 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error